Altay Therapeutics is a biotechnology company developing first- and best-in-class oral small-molecule inhibitors that directly target transcription factors. Its pipeline includes a DUX inhibitor for facioscapulohumeral muscular dystrophy (FSHD), a potent STAT inhibitor for inflammatory diseases and oncology, and additional oncology programs. The platform identifies dynamic allosteric sites to design highly selective compounds, aiming to deliver differentiated therapies for patients with limited treatment options.